Dr. Mehta joined The Column Group as a Venture Partner in 2024. Previously, Dr. Mehta was an Entrepreneur-in-Residence at Third Rock Ventures, a gastrointestinal oncologist at the Massachusetts General Hospital Cancer Center and a physician scientist running a hybrid computational and experimental research group at the Broad Institute. At the Massachusetts General Hospital, Dr. Mehta led a translational program focused on gastrointestinal tumor immunology leveraging single cell and spatial transcriptomics of patient samples and developing computational methods for the analyses of these data. At the Broad Institute, Dr. Mehta ran a basic research program focused on pancreatic cancer plasticity using functional genomics, lineage tracing and image-based screening technologies. At Third Rock Ventures, Dr. Mehta held various clinical, translational and scientific roles as he helped conceive of and build Abata Therapeutics, and later Asher Biotherapeutics and Clasp Therapeutics, as a founding team member through launch.

Dr. Mehta earned his undergraduate degree in mathematics and chemistry at Duke University, his MD degree at the David Geffen School of Medicine at UCLA and his PhD degree at the California Institute of Technology in the lab of Dr. David Baltimore. He later completed his internal medicine residency at the Massachusetts General Hospital Stanbury Physician Scientist Pathway and his hematology / oncology fellowship at the Dana Farber Cancer Institute and Harvard CancerCare during which time he did his postdoctoral research with Dr. Eric Lander and Dr. Nir Hacohen at the Broad Institute. Clinically, he continues to see gastric and pancreatic cancer patients.